Siren Therapeutics, a Resident Company of the Hongcheon National Antibody Cluster
Signs Agreement for the "2026 Super-Gap Startup Project" with the Ministry of SMEs and Startups

Hongcheon County in Gangwon Province (Governor Shin Youngjae) announced on April 3 that Siren Therapeutics Co., Ltd., a company located in the Hongcheon National Antibody Cluster, has signed an agreement for the "2026 Super-Gap Startup Project (DIPS)" hosted by the Ministry of SMEs and Startups and the Korea Institute of Startup & Entrepreneurship Development on April 1. Siren Therapeutics will now begin full-scale commercialization of its next-generation antibody-drug conjugate (ADC) platform, "E-MASK CD 155 ADC."

Bio Cluster Complex. Provided by Hongcheon County

Bio Cluster Complex. Provided by Hongcheon County

View original image

The "Super-Gap Startup Project" is a national deep-tech support program that selects promising companies with core technologies and growth potential in emerging industries, providing up to three years of support for technology commercialization and scaling up. In addition to funding for commercialization, selected companies receive follow-up growth support programs, including technical collaboration, investment linkage, and preferential access to technology guarantees.


This selection is significant in that a domestic antibody-based biotech venture has been recognized for its competitiveness within a national deep-tech support framework based on its proprietary platform technology. Siren Therapeutics has focused on developing antibody therapeutics for cancer, leveraging its antibody discovery and engineering capabilities, and is fostering the E-MASK ADC platform targeting CD 155 as a core commercialization project.


"E-MASK CD 155 ADC" is a next-generation ADC platform designed to be selectively activated within the tumor microenvironment. Through this approach, the company aims to lower the safety risks associated with exposure to normal tissues—a recurring issue in conventional ADC development—while maintaining or enhancing antitumor efficacy. In addition, Siren Therapeutics plans to enhance the platform’s commercialization completeness by building on its accumulated expertise in antibody design, masking technology, multi-antibody expansion potential, and linker-payload optimization at the non-clinical stage.


Siren Therapeutics strengthened its R&D and commercialization foundation by relocating its headquarters to the Hongcheon National Antibody Cluster in 2025. The company plans to systematically secure research support, collaboration networks, and commercialization opportunities necessary for antibody drug development by leveraging this foundation.


In particular, the company has expanded its external collaboration base by also being selected for the 2025 Gangwon-Celltrion Open Innovation Support Program. Based on cooperative relationships with regional innovation institutions and industry partners, Siren Therapeutics is simultaneously strengthening its capabilities in technology validation and business development. With the signing of the Super-Gap Project agreement, the company aims to further accelerate the non-clinical advancement of "E-MASK CD 155 ADC" and prepare for technology transfer.



CEO Yoon Sangsoon stated, "The agreement for the Super-Gap Startup Project is official recognition of Siren Therapeutics' antibody engineering capabilities and the commercialization potential of the 'E-MASK CD 155 ADC' platform," adding, "We will actively utilize various support from Hongcheon County and Gangwon Technopark, as well as open innovation networks, to further enhance our non-clinical competitiveness and business development outcomes."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing